Cargando…
Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinedion...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Inc
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721962/ https://www.ncbi.nlm.nih.gov/pubmed/19684847 http://dx.doi.org/10.1111/j.1753-5174.2008.00015.x |
_version_ | 1782170263526309888 |
---|---|
author | Güler, Serdar Sharma, Surendra Kumar Almustafa, Majeed Kim, Chong Hwa Azar, Sami Danciulescu, Rucsandra Shestakova, Marina Khutsoane, Duma Bech, Ole Molskov |
author_facet | Güler, Serdar Sharma, Surendra Kumar Almustafa, Majeed Kim, Chong Hwa Azar, Sami Danciulescu, Rucsandra Shestakova, Marina Khutsoane, Duma Bech, Ole Molskov |
author_sort | Güler, Serdar |
collection | PubMed |
description | AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinediones (TZD) after failing oral antidiabetic drugs (OADs) treatment. METHODS: This was a multi-national, multi-centre, six-month, prospective, open-labelled, uncontrolled, clinical experience evaluation study, with the exception of a three-month study in one country (China) (“all exclude China” and “China”). Initiation and discontinuation of BIAsp 30 treatment were entirely at the discretion of the attending physicians. RESULTS: Mean HbA(1c), FPG and PPPG were significantly reduced from baseline at three and six months in all groups (P < 0.001). In “all exclude China”, reductions in mean HbA(1c), FPG and PPPG at six months were as follows: BIAsp 30-only group (−2.12 ± 1.76% points; −4.82 ± 3.86 mmol/L; −6.89 ± 4.74 mmol/L), BIAsp 30 + BI group (−2.24 ± 1.77% points; −4.48 ± 3.68 mmol/L; −6.66 ± 4.55 mmol/L), BIAsp 30 + SU group (−1.95 ± 1.59% points; −3.98 ± 3.19 mmol/L; −6.25 ± 4.45 mmol/L) and BIAsp 30 + SU + BI group (−1.78 ± 1.20% points; −3.57 ± 2.78 mmol/L; −5.89 ± 3.98 mmol/L). The only serious adverse drug reaction was reported by the BIAsp 30-only group. In the “China” group, reductions in mean HbA(1c), FPG and PPPG at three months were: BIAsp 30-only group (−2.16 ± 1.52% points; −3.34 ± 2.49 mmol/L; −6.29 ± 3.92 mmol/L), BIAsp 30 + BI group (−2.44 ± 1.52% points; −4.01 ± 2.50 mmol/L; −7.10 ± 3.96 mmol/L), BIAsp 30 + GI group (−2.33 ± 1.41% points; −4.34 ± 2.52 mmol/L; −7.97 ± 3.99 mmol/L) and BIAsp 30 + BI + TZD group (−1.21 ± 1.60% points; −3.50 ± 2.29 mmol/L; −5.97 ± 3.39 mmol/L). No serious ADR were reported in China. The most frequent hypoglycaemic episodes were diurnal and minor in nature. CONCLUSIONS: BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing OADs. |
format | Text |
id | pubmed-2721962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Blackwell Publishing Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-27219622009-08-14 Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results Güler, Serdar Sharma, Surendra Kumar Almustafa, Majeed Kim, Chong Hwa Azar, Sami Danciulescu, Rucsandra Shestakova, Marina Khutsoane, Duma Bech, Ole Molskov Arch Drug Inf Original Articles AIMS: This paper presents the treatment outcomes for patients intiated on biphasic insulin aspart 30 (BIAsp 30) treatment: BIAsp 30-only, BIAsp 30 + sulphonylureas (SU), BIAsp 30 + biguanides (BI), BIAsp 30 + SU + BI, BIAsp 30 + alpha-glucosidase inhibitors (GI), and BIAsp 30 + BI + thiazolidinediones (TZD) after failing oral antidiabetic drugs (OADs) treatment. METHODS: This was a multi-national, multi-centre, six-month, prospective, open-labelled, uncontrolled, clinical experience evaluation study, with the exception of a three-month study in one country (China) (“all exclude China” and “China”). Initiation and discontinuation of BIAsp 30 treatment were entirely at the discretion of the attending physicians. RESULTS: Mean HbA(1c), FPG and PPPG were significantly reduced from baseline at three and six months in all groups (P < 0.001). In “all exclude China”, reductions in mean HbA(1c), FPG and PPPG at six months were as follows: BIAsp 30-only group (−2.12 ± 1.76% points; −4.82 ± 3.86 mmol/L; −6.89 ± 4.74 mmol/L), BIAsp 30 + BI group (−2.24 ± 1.77% points; −4.48 ± 3.68 mmol/L; −6.66 ± 4.55 mmol/L), BIAsp 30 + SU group (−1.95 ± 1.59% points; −3.98 ± 3.19 mmol/L; −6.25 ± 4.45 mmol/L) and BIAsp 30 + SU + BI group (−1.78 ± 1.20% points; −3.57 ± 2.78 mmol/L; −5.89 ± 3.98 mmol/L). The only serious adverse drug reaction was reported by the BIAsp 30-only group. In the “China” group, reductions in mean HbA(1c), FPG and PPPG at three months were: BIAsp 30-only group (−2.16 ± 1.52% points; −3.34 ± 2.49 mmol/L; −6.29 ± 3.92 mmol/L), BIAsp 30 + BI group (−2.44 ± 1.52% points; −4.01 ± 2.50 mmol/L; −7.10 ± 3.96 mmol/L), BIAsp 30 + GI group (−2.33 ± 1.41% points; −4.34 ± 2.52 mmol/L; −7.97 ± 3.99 mmol/L) and BIAsp 30 + BI + TZD group (−1.21 ± 1.60% points; −3.50 ± 2.29 mmol/L; −5.97 ± 3.39 mmol/L). No serious ADR were reported in China. The most frequent hypoglycaemic episodes were diurnal and minor in nature. CONCLUSIONS: BIAsp 30 treatment in a clinical setting improved glycaemic control in type 2 diabetes patients failing OADs. Blackwell Publishing Inc 2009-06 /pmc/articles/PMC2721962/ /pubmed/19684847 http://dx.doi.org/10.1111/j.1753-5174.2008.00015.x Text en © 2009, Archives of Drug Information http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Original Articles Güler, Serdar Sharma, Surendra Kumar Almustafa, Majeed Kim, Chong Hwa Azar, Sami Danciulescu, Rucsandra Shestakova, Marina Khutsoane, Duma Bech, Ole Molskov Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results |
title | Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results |
title_full | Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results |
title_fullStr | Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results |
title_full_unstemmed | Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results |
title_short | Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results |
title_sort | improved glycaemic control with biphasic insulin aspart 30 in type 2 diabetes patients failing oral antidiabetic drugs: present study results |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721962/ https://www.ncbi.nlm.nih.gov/pubmed/19684847 http://dx.doi.org/10.1111/j.1753-5174.2008.00015.x |
work_keys_str_mv | AT gulerserdar improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT sharmasurendrakumar improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT almustafamajeed improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT kimchonghwa improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT azarsami improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT danciulescurucsandra improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT shestakovamarina improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT khutsoaneduma improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults AT becholemolskov improvedglycaemiccontrolwithbiphasicinsulinaspart30intype2diabetespatientsfailingoralantidiabeticdrugspresentstudyresults |